Serina Therapeutics (SER) Stock Price, News & Analysis

Company Overview

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Key Stats

• Today's Range: $2.42 to $2.67
• 50-Day Range: $1.81 to $2.87
• 52-Week Range: $1.22 to $5.83
• Volume: 70,886 shs
• Average Volume: 1.73 million shs
• Market Capitalization: $66.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Serina Therapeutics Stock Analysis - MarketRank™

Serina Therapeutics scored higher than 78% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Serina Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Serina Therapeutics has a consensus price target of $8.00, representing about 217.5% upside from its current price of $2.52.

Amount of Analyst Coverage

Serina Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Serina Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Serina Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Serina Therapeutics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.70% of the float of Serina Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Serina Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Serina Therapeutics has recently decreased by 34.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Serina Therapeutics does not currently pay a dividend.

Dividend Growth

Serina Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Serina Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

Search Interest

3 people have searched for SER on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Serina Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $19,805.00 in company stock, which represents 0.0309% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Serina Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,805.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.70% of the stock of Serina Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.50% of the stock of Serina Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:SER
• CIK: 1708599
• Web: serinatherapeutics.com
• Phone: (256) 327-9630
• Fax: 510-671-8619
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Serina Therapeutics: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +205.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.18 million
• Net Margins: N/A
• Pretax Margin: -16,358.46%
• Return on Equity: -416.40%
• Return on Assets: -132.69%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 6.65
• Quick Ratio: 6.65

Sales & Book Value

• Annual Sales: $130 thousand
• Price / Sales: 511.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 3.54

Miscellaneous

• Outstanding Shares: 25,400,000
• Free Float: 20,904,000
• Market Cap: $66.55 million
• Optionable: N/A
• Beta: 1.17